| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.080 | Biomarker | disease | BEFREE | These results support the role of aberrant chromatin accessibility and consequent oncogenic <i>MYC</i> enhancer activation in NOTCH1-induced T-ALL.<i>This article is highlighted in the In This Issue feature, p. 1631</i>. | 31519704 | 2019 | ||||
|
0.080 | Biomarker | disease | BEFREE | Two T-lymphoblastic leukemia (T-ALL) cell lines and two acute myeloblastic leukemia (AML) cell lines were transfected with siRNAs targeting NOTCH1 and NOTCH2. | 24122995 | 2013 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | Interestingly, gain-of-function mutations or cryptic transcription initiation of the Notch1 gene have been frequently found in both human and mouse T-ALL. | 22393458 | 2012 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | T-cell lymphoblastic leukemia in early childhood presents NOTCH1 mutations and MLL rearrangements. | 19631984 | 2010 | ||||
|
0.080 | AlteredExpression | disease | BEFREE | To further investigate the molecular mechanisms underlying proliferation suppression and apoptosis and explore effective downstream target genes, we used RNA interference (RNAi) technology to down-regulate the expression of Notch-1 in GSIs-resistant T-ALL cell lines. | 19091404 | 2009 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | Here we have investigated the prognostic impact of mutations in the NOTCH1 pathway, in particular, the NOTCH1 and FBXW7 genes, in a large cohort of adult patients with T-lymphoblastic leukemia (n=126). | 19794083 | 2009 | ||||
|
0.080 | Biomarker | disease | BEFREE | Using parallel studies in T cell progenitors and established T-ALL lines we have demonstrated that the NFkappaB signaling pathway is targeted and induced by Notch1 activation. | 17329966 | 2007 | ||||
|
0.080 | Biomarker | disease | BEFREE | These results show that the CUTLL1 cell line has a strong dependence on NOTCH1 signaling for proliferation and survival and supports that T-ALL patients whose tumors harbor t(7;9) should be included in clinical trials testing the therapeutic efficacy NOTCH1 inhibition with GSIs. | 16688224 | 2006 |